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Human kallikrein-related peptidase 4 (KLK4/pros-
tase), a trypsin-like serine protease, is a potential
target for prostate cancer treatment because of its
proteolytic ability to activate many tumorigenic and
metastatic pathways including the protease activated
receptors (PARs). Currently there are no KLK4-
specific small-molecule inhibitors available for thera-
peuticdevelopment.Herewere-engineer thenaturally
occurring sunflower trypsin inhibitor to selectively
block the proteolytic activity of KLK4 and prevent
stimulation of PAR activity in a cell-based system.
The re-engineered inhibitor was designed using a
combination ofmolecularmodeling andsparsematrix
substrate screening.
INTRODUCTION
Prostate cancer is responsible for 10% of all male cancer deaths
in the United States (Jemal et al., 2008) and is the most common
newly diagnosed cancer in men. Current treatments for prostate
cancer focus on androgen deprivation and are associated with
a plethora of side effects (Malone et al., 2005) with no effective
treatment available for late stages of the disease. Kallikrein-
related peptidase 4 (KLK4) is a member of the tissue kallikrein
family of serine proteases. It is predominantly expressed in basal
and secretory cells of the prostate gland and is overexpressed in
malignant prostate tumors (Veveris-Lowe et al., 2005; Xi et al.,
2004). A series of in vitro studies have shown that KLK4
possesses proteolytic activities that are strongly linked to the
development and progression of cancer. For example, KLK4
cleaves fibrinogen (Obiezu et al., 2006), a basic constituent of
the extracellular matrix and an important factor in metastasis
(Coughlin, 1999). Other relevant proteins targeted by KLK4
include collagen I and IV (Obiezu et al., 2006), prostatic acid
phosphatase (Takayama et al., 1997), insulin-like growth factor
binding protein (Matsumura et al., 2005), and urokinase plasmin-
ogen activator receptor (uPAR) (Beaufort et al., 2006).Chemistry & Biology 16, 6Very recent studies have shown that KLK4 is also able to stim-
ulate the activity of the protease activated receptors, PAR-1 and
PAR-2 (Mize et al., 2008; Ramsay et al., 2008b), causing
increased cell migration and proliferation. The PARs are a
subfamily of the G-protein-coupled receptors that do not bind
a soluble ligand, but instead are activated by specific proteolytic
cleavage at their amino termini. This cleavage creates a new
amino terminus that acts as a tethered ligand enabling receptor
signaling (Coughlin, 2005; Hollenberg, 2003). Recently it was
found that PAR-1 and PAR-2 were overexpressed in prostate
cancer and that PAR-1- and PAR-2-specific agonists caused
RhoA-dependent cytoskeletal remodelling (Mize et al., 2008).
Furthermore, a number of other cancers show PAR-driven
growth (Darmoul et al., 2001), invasion (Even-Ram et al., 1998;
Henrikson et al., 1999), and metastasis (Nierodzik et al., 1998).
Of note, KLK4 is associated with an epithelial to mesenchymal
transition-like effect and increased in vitro cell migration rates
(Veveris-Lowe et al., 2005), which might reflect a PAR-induced
event. KLK4 is also highly expressed in bone metastasis and
thus might be involved in metastatic spread to bone tissue
(Gao et al., 2007). These observations suggest KLK4 plays an
important role in prostate cancer. However, there are currently
no KLK4-specific small-molecule inhibitors, nor are there
specific inhibitors available for the other 15 members of the kalli-
krein-related peptidase group of enzymes to which KLK4
belongs. This lack might reflect the difficulty associated with
selective inhibition of an individual member of a closely related
superfamily of enzymes. Indeed, the kallikreins share very high
homology when considering the surface of their active sites,
with KLK14 and KLK4 showing 85% amino acid identity within
5 A˚ of their catalytic triads. Despite the lack of synthetic inhibi-
tors, there are a number of naturally occurring molecules that
can block serine protease activity including sunflower trypsin
inhibitor (SFTI or SFTI-1).
SFTI belongs to the Bowman-Birk serine protease inhibitor
family and is a potent inhibitor of trypsin and cathepsin G, and
a suppressor of tumorigenesis 14 (ST14/matriptase/MT-SP1).
It was recently discovered in sunflower (Helianthus annus) seeds
and characterized by determination of its three-dimensional
structure in complex with bovine b-trypsin (Luckett et al.,
1999). Trypsin exhibits a high level of sequence homology to33–643, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 633
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the catalytic triad), suggesting that SFTI might also inhibit this
enzyme. Despite SFTI’s considerable potential as a generic
protease inhibitor, to date there have been no systematic
attempts to engineer the molecule to produce a potent and
highly selective protease inhibitor.
This study focuses on production of a potent and selective
KLK inhibitor by substrate guided design methods. KLK4 was
chosen to initiate this study because its peptide substrate spec-
ificity has recently been investigated in two studies using posi-
tional scanning synthetic combinatorial libraries (PS-SCL) of tet-
rapeptides (Debela et al., 2006; Matsumura et al., 2005). In both
studies, individual peptide substrates representative of optimal
sequences were not assayed. Furthermore, there were dispar-
ities between the two studies regarding ranking of cleavage sites
for KLK4, suggesting that the optimal KLK4 cleavage specificity
is yet to be defined. Accordingly, we set out to design a sparse
matrix peptide library of 125 individual tetrapeptide-para-nitroa-
nilides (pNAs) representing all possible combinations in position
P2, P3, and P4 of the five highest scoring residues in the previous
study of Matsumura and co-workers (Matsumura et al., 2005). In
contrast to this previous study, we chose to synthesize our
library in serial mode (individually) rather than through a multi-
plexed (mixed) PS-SCL scheme. Once found, the optimal
cleavage sequence formed the basis for re-engineering of SFTI
and production of a potent inhibitor that could provide a novel
treatment for KLK4-driven effects in prostate cancer.
RESULTS
Rational Design of a Small-Molecule KLK4 Inhibitor
Our design strategy consisted of three discrete steps. Initially we
screened a focused tetrapeptide library of pNA substrates to
determine the optimal substrate for KLK4, which revealed that
the sequence FVQR outperformed previous candidate sub-
strates. We then used this sequence to design an intermediate
peptide aldehyde inhibitor to verify our hypothesis that efficient
substrates for KLK4 could also be used as the basis of efficient
inhibitors, and finally substituted the optimal tetrapeptide se-
quence into the SFTI scaffold to produce an inhibitor with an
amidolytic Ki of 3.59 ± 0.28 nM.
KLK4 Has a Marked Preference for a Phenyl Group
at P4 and FVQR Is its Optimal Tetrapeptide Substrate
Enhancement of the potency and selectivity of inhibition of the
wild-type SFTI toward KLK4 required a detailed knowledge of
the enzyme’s ligand-binding determinants. Accordingly, we pro-
bed the enzyme active site with a sparsematrix library of chromo-
genic peptide substrates. Results from the library screen are
summarized in Figure 1. The substrate FVQR-pNA was hydro-
lyzed most efficiently (6.7 times average rate) followed by FTQR-
pNA and IVQR-pNA (4.4 and 4.3 times average rates, respec-
tively). Significantly, IVQR had previously been predicted to be
the optimal tetrapeptide substrate for KLK4 (Debela et al., 2006).
KLK4 has previously been shown to have highest amidolytic
activity toward the standard tripeptide substrate Bz-FVR-pNA
out of all experimentally tested colorimetric peptide substrates
(Matsumura et al., 2005). Therefore, we decided to use this
substrate as a benchmark when determining KLK4’s enzymatic634 Chemistry & Biology 16, 633–643, June 26, 2009 ª2009 Elsevieactivity toward FVQR-pNA. A number of peptide pNA substrates
were synthesized, purified, and further characterized. Given the
preference for phenyl and bulky hydrophobic residues at the
N terminus of the peptide substrates as determined in these
studies, we examined the contribution of the benzoyl capping
group of Bz-FVR-pNA to its apparent preference as an amido-
lytic substrate for KLK4. Accordingly, we evaluated an acety-
lated variant, Ac-FVR-pNA, and because IVQR scored second
best in the sparse matrix library and had previously been sug-
gested to be the optimal KLK4 cleavage sequence (Debela
et al., 2006), IVQR-pNA was also included. In addition, we also
synthesized FVMR-pNA to assess the importance of the prefer-
ence we observed for the polar glutamine residue in the P2 posi-
tion by replacing it with a more hydrophobic methionine residue.
Kinetic data for these substrates are summarized in Table 1.
KLK4 showed highest amidolytic activity toward FVQR-pNA of
all chromogenic substrates examined. Replacing the N-terminal
benzoyl group of Bz-FVR-pNA with an acetyl group resulted in
a 47% reduction of kcat whereas replacing Phe with Val at the
P4 position resulted in an 87% reduction of kcat, indicating an
important role of the benzene ring in the interaction with KLK4
at the P4 position. The considerable reduction in kcat as a result
of replacing Gln with Met in the S2 or P2 position suggests that
the polarity of the Gln side chain plays an important role in the
rate of hydrolysis of this substrate. As a result of this, we used
the sequence FVQR as the basis of inhibitor design rather than
IVQR and FQQR, as predicted previously (Matsumura et al.,
2005; Debela et al., 2006), or the commercially available tripep-
tide benzoyl FVR-pNA that until now has been considered the
substrate with highest kcat.
Peptide Aldehydes Based on Substrate Sequences
Are Inhibitors of KLK4
We hypothesized that sequences that were efficient substrates
for KLK4 would be complementary to the S1–S4 subsites of
the enzyme’s catalytic center. Consequently, we created a series
of peptide aldehydes based on the optimal sequence from our
sparse matrix peptide library, the best substrate predicted by
PS-SCL (IVQR) and an aldehyde based on Bz-FVR-pNA. The
aldehyde groups on these compounds mimic the transition state
of the amidolytic reaction, producing molecules that inhibit
proteolysis. The two library-based aldehydes inhibited KLK4
amidolytic activity at micromolar levels, whereas Bz-FVR alde-
hyde did not inhibit KLK4 in this range (data not shown). FVQR
aldehyde was the most efficient inhibitor by an order of magni-
tude with an IC50 of 10.8 ± 1.3 mM compared with 103.3 ±
2.8 mM for IVQR. Although these levels of inhibition are not ther-
apeutically useful, they serve to validate our approach.
KLK4 Is Inhibited by Wild-Type SFTI
Given that trypsin and KLK4 share significant structural (root-
mean-square deviation [rmsd] = 1.1 A˚ over 223 Ca atoms) and
sequence similarity (40% overall and 73% identity within the
area adjacent to SFTI in the crystal structure, PDB ID 1SFI) and
are both trypsin-like serine proteases, we reasoned that SFTI
would be able to inhibit KLK4 in addition to trypsin. Assays
with the amidolytic standard KLK4 substrate Bz-FVR-pNA
showed that the wild-type inhibitor could indeed block KLK4
activity with an IC50 of 221.4 ± 1.1 nM.r Ltd All rights reserved
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KLK4 showed a marked preference for the sequence FVQR as
a substrate for cleavage and as an aldehyde inhibitor. Accord-
ingly, we decided to substitute this sequence into the SFTI back-
bone to increase the scaffold’s potency of inhibition. The variant
SFTI molecule was designed such that the key P1 residue (Lys5)
was replaced by arginine, with glutamine replacing Thr4. Cys3
Figure 1. Amidolytic Activity of KLK4
against Sparse Matrix Library pNA Sub-
strates
The y axis represents the rate of substrate
cleavage in mOD/min(405), with the amino acid
at position P2 indicated beside each y axis. The
x axis labels the bars corresponding to substrates
with each of the 25 combinations of the amino
acids in the P4 and P3 positions. Arginine was
kept constant in the P1 position while varying the
amino acid in positions P2–P4 as indicated in the
graph. Data represent mean and standard error
of the mean (± SEM) of three experiments in tripli-
cate.
was not substituted given the pivotal
role of this residue in the structural
stability of SFTI, while Arg2 was replaced
by phenylalanine. Inhibitory potency of
the resulting variant (SFTI-FCQR) was
evaluated against KLK4. Enzyme veloci-
ties were monitored with varying inhibitor
concentration in the range of 2.0 mM to
1 nM to determine IC50 (Bz-FVR-pNA;
0.12 mM) and Ki (FVQR-pNA) values.
SFTI-FCQR was determined to be a po-
tent KLK4 inhibitor with an IC50 of 7.97 ±
1.08 nM and a Ki of 3.59 ± 0.28 nM
(Table 2).
Wild-type SFTI displays promiscuous
inhibition, blocking the activity of diverse
proteases including suppressor of tu-
morigenesis 14 (ST14/matriptase) andca-
thepsin G in addition to trypsin. Accord-
ingly, we assayed a panel of serine
proteases including trypsin, thrombin,
a-chymotrypsin, Streptomyces griseus
typeXIVprotease, plasminogenprotease,
and suppressor of tumorigenesis 14
ST14/matriptase to assess their inhibition
by SFTI-FCQR. We found that the SFTI
variant did not inhibit any of these prote-
ases, with the exception of trypsin, which
wasonly inhibited in themicromolar range
(IC50 4.064 ± 1.088 mM; Table 2). As a
further test of the inhibitor’s selectivity we
also tested the closely related trypsin-like
serine proteases of the kallikrein related
peptidase superfamily, namely KLK2, 5
and 14. KLK14 in particular shares 85%
amino acid identity with KLK4 within 5 A˚
of the active site catalytic triad and yet SFTI-FCQR only in-
hibited the enzyme at micromolar levels (see Table 2).
While inhibition of serine proteases is most usually measured
using small peptide and ester substrates, the important biolog-
ical activities of the enzymes are the result of protein proteolysis.
Given this, we also assayed both the wild-type and FCQR variant
inhibitors for their ability to inhibit KLK4 proteolysis of fibrinogen,
Chemistry & Biology 16, 633–643, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 635
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Substrate KM kcat kcat/KM
Bz-FVR-pNA 42.5 ± 5.9 mM 1.89 ± 0.10 s1 41.54 ± 4.65 3 103 M1 s1
Ac-FVR-pNA 194.9 ± 41.4 mM 1.00 ± 0.11 s1 1.00 ± 0.11 3 103 M1 s1
FVMR-pNA 74.7 ± 10.3 mM 1.27 ± 0.063 s1 17.00 ± 0.50 3 103 M1 s1
IVQR-pNA 183.1 ± 12.14 mM 2.10 ± 0.23 s1 11.47 ± 0.23 3 103 M1 s1
FVQR-pNA 679.9 ± 113.1 mM 15.7 ± 1.57 s1 23.09 ± 0.63 3 103 M1 s1a known substrate for the enzyme (Obiezu et al., 2006). Surpris-
ingly, inhibition of fibrinogen proteolysis did not reflect inhibition
of peptide-pNA hydrolysis. The FCQR variant was found to be
a potent inhibitor of fibrinogen proteolysis by KLK4, with
complete inhibition at 250 nM (Figure 2A). Unexpectedly, no inhi-
bition of proteolysis by KLK4 could be detected for the wild-type
inhibitor even at a concentration of 2 mM, compared to a
substrate concentration of 0.8 mM and an enzyme concentration
of 2.5 nM (Figure 2A), a marked contrast to the inhibition of ami-
dolytic activity. Similarly, the SFTI-FCQR variant showed no inhi-
bition of tryptic digestion of fibrinogen up to a concentration of
2 mM (Figure 2B), or with KLK2, 5, 12, and 14 (see Figures 2C–2F).
SFTI-FCQR Maintains its Inhibitory Activity
with a Half-Life of 4 Days in Tissue Culture
To gauge the half-life of SFTI-FCQR in a cellular environment, we
incubated STFI-FCQR at a concentration of 1 mM with LNCaP,
22Rv1, and PC3 prostate cancer cell lines. Residual SFTI-
FCQR inhibitory activity wasmeasured in tissue culture superna-
tants that had been boiled and centrifuged to remove serum
derived protease inhibitors. Assaying a 1:5 dilution of tissue
culture supernatant (200 nM concentration at time = 0) against
recombinant KLK4 gave complete inhibition even after a week
of contact with prostate cancer cells (data not shown). Dilutionby a further 20-fold was required before any appreciable reduc-
tion of inhibitory activity could be observed. Half-lives for inhib-
itor incubated with LNCaP and 22Rv1 were similar (Figure 3;
t1/2 = 119 hr and 117 hr, respectively), whereas the decline in inhi-
bition was accelerated in PC3s (t1/2 = 89hr). Decay of inhibition
followed a secondary polynomial relationship, with the exponen-
tial component being concurrent for all three cell lines, whereas
the linear component was nearly five times greater in the pres-
ence of PC3s. This difference might correlate with the higher
metabolic rate observed in this cell line compared with LNCaP
and 22Rv1 as determined by WST-1 assays (data not shown).
Although these half-life measurements do not allow estimation
of in vivo clearance from circulation via the kidneys, they argue
that SFTI-FCQR enjoys considerable stability in the cellular
milieu.
SFTI-FCQR Blocks KLK4 Stimulated Calcium Flux
in Cell-Based Assays
Recent work has demonstrated that KLK4 is able to stimulate the
protease activated receptors PAR-1 and PAR-2, causing release
of intracellular calcium, phosphorylation of ERK1/2, and ulti-
mately increasing rates of proliferation in DU145 prostate cancer
cells (Ramsay et al., 2008b; Mize et al., 2008). These effects
could be blocked by the nonspecific protease inhibitor aprotinin.Table 2. Inhibitory Properties of Wild-Type SFTI and SFTI-FCQR
Enzyme Inhibitor Ki (nM) Substrate IC50 (nM) Substrate (0.1 mM)
KLK4 SFTI-1 — — 221.4 ± 10.1 Bz-FVR-pNA
SFTI-FCQR 3.59 ± 0.28 FVQR-pNA 7.97 ± 1.08 FVQR-pNA
KLK2 SFTI-FCQR — — >10,000 Bz-PFR-pNA
KLK5 SFTI-FCQR — — 2348 ± 721 Bz-PFR-pNA
KLK14 SFTI-FCQR — — 1506 ± 37.1 Ac-GSLR-pNA
b-Trypsin SFTI-1 0.1a BAPNA — —
SFTI-FCQR — — 4064 ± 1088 BAPNA
Thrombin SFTI-1 136a Unknown — —
5050b N-t-Boc-LRR-AMC — —
SFTI-FCQR — — >10,000 Bz-FVR-pNA
Matriptase SFTI-1 0.92b N-t-Boc-QAR-AMC — —
SFTI-FCQR — — >10,000 Bz-FVR-pNA
a-Chymotrypsin SFTI-1 2300 ± 100c N-succinyl-AAPP-pNA 1800 ± 110 W-pNA
SFTI-FCQR — — >10,000 W-pNA
Plasminogen SFTI-FCQR — — >10,000 L-pNA, BAPNA
Streptomyces griseus type XIV protease SFTI-FCQR — — >10,000 L-pNA, BAPNA
a Luckett et al., 1999
b Long et al., 2001
cDescours et al., 2002
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A Kallikrein-Related Peptidase InhibitorFigure 2. Inhibition of serine protease proteolytic activity by SFTI and SFTI-FCQR
Kallikrein and trypsin-mediated proteolysis of fibrinogen assessed by SDS-PAGE. Proteolytic products are visualized by Coomassie blue staining following reso-
lution on 12% polyacrylamide gels.
(A) Effect of increasing concentrations of SFTI-FCQR on fibrinogen digestion by KLK4 and SFTIwt at a concentration of 2000 nM.
(B) Trypsin digestion of fibrinogen in the presence and absence of 2000 nM SFTI-FCQR.
(C–F) Digestion of fibrinogen by KLK2, 5, 12, and 14, respectively, in the presence of increasing concentrations of SFTI-FCQR. Gels are representative of three
independent experiments.We reasoned that SFTI-FCQR should also be able to block this
activity, and assessed the inhibitor’s effect on KLK4 stimulated
calcium release in cell-based assays. The inhibitor showed
extremely robust blockade of calcium release when stimulatedChemistry & Biology 16,byKLK4 treatment in the presence of 1 mMSFTI-FCQR (Figure 4).
Furthermore, the inhibitor was selective, blocking KLK4 only and
being permissive for calcium release by both trypsin and PAR-2-
activating peptide.633–643, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 637
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To gain a molecular understanding of the behavior of the
substituted SFTI variant, we carried out predictive modeling of
an SFTI-FCQR/KLK4 complex using the SFTI/trypsin structure
1SFI and the KLK4 structure 2BDG as starting point. Trypsin
and KLK4 superimpose closely, with an RMSD of 1.1 A˚ over
223 Ca atoms. Active site regions superimpose extremely well,
with the exception of residues that form the S4 subsite: residues
95–98 (the ‘‘99 loop’’) fold back, away from the active site of
KLK4 in comparison with trypsin (Figure 5A), resulting in differ-
ences of up to 3 A˚; residues in the 164–180 loop also display
large differences. These differences have two important conse-
quences. First, the side chains of L98, L99, and L175 in KLK4
move toward the S4 pocket, making it more hydrophobic.
Second, the negative S2 pocket, with D102 (catalytic) at its
base, widens and deepens, making it accessible by the
Figure 3. Stability of SFTI-FCQR in Contact with Prostate Cancer
Cells In Vitro
Residual SFTI-FCQR was assayed in cell culture media from prostate cancer
cells treated with a single 1 mM dose of inhibitor at time 0. Endogenous inhib-
itors were removed by boiling followed by centrifugation to remove precipi-
tated denatured protein. Stability was assessed against LNCaP (closed
circles), 22RV1 (open circles), and PC3 cells (triangles). Data are mean ±
SEM from three experiments in triplicate.substituted Gln in the SFTI-FCQR variant, which can H-bond
with residues lining the pocket (Figures 5D and 5E).
Structural similarities between KLK4 and trypsin were re-
flected in the predicted structure for the SFTI-FCQR variant.
The variant SFTI was modeled by simple substitution of the
wild-type structure coupled with rotamer-based side-chain
modeling and energy minimization. This produced only subtle
atomic shifts that relieved close atomic contacts. Each substitu-
tion and subsequent structural changes in the context of KLK4-
trypsin structural differences is discussed below. Particular
attention is drawn to the net balance of hydrogen bonds and
nonpolar interactions at the site of substitution.
K5R (P1): The most statistically preferred Arg rotamer corre-
lates well with thewild-type Lys side-chain conformation. Energy
minimization relieves a close contact of K5 with S190 in the
trypsin-SFTI complex and the modeled SFTI R5 side chain
forms two hydrogen bonds with D189 at the base of the electro-
negative S1 pocket (Figures 5B and 5D). However, an intramo-
lecular hydrogen bond with S10 is lost.
T4Q (P2): Substitution of the Thr side chain in SFTI removes
two intramolecular hydrogen bonds, with S6 and I10 of SFTI
(Figure 5B). However, T4 does not hydrogen-bond with the
protease. Modeling a Gln at this position (using the second
most statistically preferred rotamer) in the SFTI-FCQR allows
two hydrogen bonds between its side-chain amide group and
the protease (catalytic H57 side chain and S214 main chain;
Figure 5C). In addition, when adopting this conformation, the
relatively larger side chain of Gln fits snugly into the S2 pocket
that is wider in KLK4 compared with trypsin (Figures 5D and 5E).
R2F (P4): The side chain of R2 in SFTI forms a hydrogen bond
with the backbone of N97 of trypsin. A Phe at this position in
SFTI-FCQR can be modeled satisfactorily using the most
preferred rotamer, and makes nonpolar interactions with the
side chains of L175 and F215 of the protease. In response to
substitution, small movements of the side chain of D14 of the
inhibitor (in order to remove unfavorable close contacts) result
in the loss of a hydrogen bond between D14 and the SFTI
backbone.
The preferences for residues at P1, P2, and P4 can be ex-
plained largely by the physicochemical nature of each subsite
in the modeled complex, with the exception of the poor prefer-
ence for Tyr at P4, compared with Phe. Indeed, in the currentFigure 4. Effect of SFTI-FCQR on Calcium
Release in Cell-Based Assays
Lung murine fibroblasts (LMF) stably expressing
human PAR-2 were incubated after 30 s with
either activated insect cell-derived KLK4 (iKLK4,
300 nM), trypsin (10 nM), or PAR-2-activating
peptide (100 nM) with or without SFTI-FCQR
(1 mM). The fluorescence at 510 nmwasmeasured
following alternating excitation at 340 and 380 nm
(Em510[340/380]). The ratio of Em510(340/380)
is proportional to intracellular Ca2+ ion con-
centration. The data are represented as mean of
three experiments in triplicate. Treatment with (A)
buffer or (B) SFTI-FCQR only had no effect
whereas treatment with (C) trypsin, (D) iKLK4, (E)
trypsin and SFTI-FCQR, or (F) PAR-2-activating
peptide resulted in increased intracellular Ca2+ ion concentration. Calcium fluxwas restored in cells initially treated with iKLK4 and SFTI-FCQR at 30 s by addition
of (G) trypsin or (H) PAR-2-activating peptide after 3.5 min. Arrows indicate injection points for solutions as indicated.
638 Chemistry & Biology 16, 633–643, June 26, 2009 ª2009 Elsevier Ltd All rights reserved
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the Phe, with neighboring polar groups positioned to form
hydrogen bonds with its OH moiety. The poor preference for
Tyr could be explained by assuming an alternative side-chain ro-
tamer that positions its side chain deeper into the hydrophobic
core created by residues L99, L175, and F215 (data not shown).
The absence of polar hydrogen-bonding partners for the OH
moiety would destabilize this residue, rationalizing the experi-
mental data presented here. However, modeling Tyr at this posi-
tion produces several close contacts with neighboring residues
that can only be relieved by relatively large structural rearrange-
ments in the surroundings. These cannot be modeled with any
accuracy using current molecular simulation techniques, and
therefore a full structural rationalization must await high-resolu-
tion crystallographic analysis.
DISCUSSION
This study has used substrate-based and computer-aided
design to develop a highly selective protease inhibitor that can
Figure 5. Structural Characteristics of the
Protease-Inhibitor Interfaces for the Tryp-
sin-SFTI and the Modeled KLK4/SFTI-
FCQR Complex
Catalytic residues are labeled with an asterisk.
SFTI residues that have been substituted in this
study are labeled in green.
(A) Superposition between trypsin (cyan)-SFTI
(green) complex (1SFI) and KLK4 (1BD1, pink) in
and around the active site, showing regions of
structural differences, notably around the ‘‘99
loop’’ (L/T98; L99) and at residue 175. Side chains
are shown and labeled for sequence differences or
where significant structural differences are
observed (KLK residue shown before trypsin
residue in label). The S2 subsite is indicated.
(B and C) Hydrogen bonds (magenta dashed lines)
between trypsin (yellow) and SFTI (green) (B), and
(C) modeled KLK4 (yellow) and SFTI-FCQR
(green). Viewed from the inverse angle compared
with all other figures in panel, i.e., view from
protease toward inhibitor.
(D and E) Molecular surfaces of (D) trypsin-SFTI
and (E) modeled KLK4-SFTI-FCQR complexes
colored according to electrostatic potential (red
indicates negative, blue is positive). Subsites are
labeled as S1, S2, etc. Structural differences
between trypsin and KLK4, notably at L95 and
L/T98, shown in A, cause an increase in the width
and depth of the electronegative S2 pocket, allow-
ing its occupation by the modeled glutamine (4Q)
side chain of SFTI-FCQR.
block signaling by protease-activated
receptors in a cellular context. Specifi-
cally, we have shown that a peptide
sequence that performs well as
a substrate for a target protease can be
substituted into the naturally occurring
SFTI scaffold to produce an inhibitor
with a nanomolar Ki. The inhibitor displayed reduced ability to
inhibit the proteases thrombin and suppressor of tumorigenesis
14 (ST14/matriptase) by three orders of magnitude and achieved
differential inhibition of trypsin-like proteases from the kallikrein
related peptidase superfamily. We have also demonstrated
that inhibition of peptide cleavage by a protease does not neces-
sarily reflect inhibition of cleavage of protein substrates, an
important caveat for screening potential lead compounds
directed at proteases. Furthermore, this study illustrates the
extreme robustness of the SFTI scaffold toward degradation in
a cellular context refuting previous studies which focused on
engineering the supposedly labile disulphide bond.
Previously we have shown that PAR-1 and PAR-2 are upregu-
lated in prostate cancer cells (Ramsay et al., 2008b) and that
PAR-1 and PAR-2 activity plays a role in proliferation and migra-
tion of prostate cancer cells (Mize et al., 2008). Accordingly, PAR
activity is an attractive target for chemotherapeutic intervention.
Here we have inhibited the stimulation of PAR-2 by its putative
cognate in vivo protease, KLK4, which is also upregulated during
prostate cancer progression. PAR-2 inhibition was assessed in
cell-based assays, which demonstrated the potency of inhibition
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a concentration of 1 mM. Significantly, the inhibitor had no effect
on trypsin stimulated calcium flux or on PAR-2 activity elicited by
an exogenously added PAR-2-activating peptide. The inhibitory
activity of SFTI-FCQR could form the basis of a novel treatment
for prostate cancer. This prospect has been enhanced by our
finding that the variant inhibitor is highly robust with a half-life
measured in days in tissue culture conditions, even when
considering PC3 cells with very high metabolic activity.
The SFTI scaffold represents an excellent platform for drug
design. With only 14 amino acids and a molecular mass of
1.513 kDa, SFTI is one of the smallest naturally occurring serine
protease inhibitors (Luckett et al., 1999) having very high potency
of inhibition (b-trypsin: Ki = 0.1nM). Comparison of the structure
of SFTI in complex with b-trypsin and in solution (Korsinczky
et al., 2001) indicates that the peptide’s conformation does not
change markedly upon binding to the protease, reflecting stabi-
lization of the inhibitor both by cyclization and a bisecting disul-
phide bond. SFTI’s disulphide bond is regarded as something of
an Achilles’ heel, with a potential for thiol-disulfide exchange
reactions with reduced glutathione and other redox active
species (Huck et al., 2006). This has led to a series of studies re-
placing the natural disulphide bond with a series of olefinic and
other substituted linkers (Li et al., 2007). Although the results of
these studies are interesting, a careful examination of the disul-
phide’s flanking sequence would have shown that it is actually
intrinsically resistant to exchange reactions. Important determi-
nants of disulfide bond stability include neighboring residues of
aromatic and amino side chains near the bond greatly reducing
and increasing the reactivity, respectively (Huck et al., 2006;
Snyder et al., 1981). The disulfide bond in SFTI-FCQR is sur-
rounded by Phe2 and Gln4 on one side and Ile10 and Phe12
on the other side. Because Gln4 is extended as far as sterically
possible away from the disulfide bond due to a hydrogen bond
with Ser6, the disulfide bond is likely to be quite stable as re-
vealed by its extended half-life in tissue-culture-based assays.
The significant factor here is that maintaining the native disul-
phide bond preserves the option of biological manufacture
through the sunflower seed system, which is not possible with
the olefinic derivatives produced in the previous studies.
SFTI’s constrained geometry and potency of inhibition have
focused drug design efforts on the molecule’s potential as
a generic scaffold for protease inhibitor construction (Hilpert
et al., 2005). An alanine scanning study of SFTI revealed little vari-
ation of the potency of inhibition after substitution of individual
residues within the molecule, with the exception of the replace-
ment of Lys5, which resulted in a 1000-fold decrease in inhibition
of bovine trypsin (Daly et al., 2006). Several other studies used
conservative substitution of amino acids around the SFTI ring
to produce inhibitors that were active against bovine trypsin,
chymotrypsin, and human elastase (Daly et al., 2006: Li et al.,
2007; Zablotna et al., 2007). However, these studies did not
examine the ability of their respective SFTI variants to inhibit
proteolysis of full-length protein substrates, but relied on inhibi-
tion of activity toward standard amidolytic substrates. Addition-
ally, they did not assess the selectivity of their inhibitors with
closely related proteases. Use of SFTI as a molecular scaffold
for designing potent and specific inhibitors is particularly chal-
lenging because of the molecule’s broad selectivity of inhibition640 Chemistry & Biology 16, 633–643, June 26, 2009 ª2009 Elsevie(Ki in the nanomolar range for the three unrelated proteases:
ST14, trypsin, and cathepsin G [Long et al., 2001]).
In contrast to the reports above, the inhibitor resulting from
these studies has both enhanced inhibitory potency and selec-
tivity. The importance of inhibitor selectivity has been highlighted
by recent failures in clinical trials of a series of metalloproteinase
(MMP) inhibitors that were developed in an attempt to block
MMP-mediated digestion of extracellular matrix components
and halt tumor progression (Chambers and Matrisian, 1997).
Some of these entered phase 3 clinical trials (Hidalgo and Eck-
hardt, 2001), although most have been terminated due to no or
negative survival benefits (Overall and Lopez-Otin, 2002). It has
been suggested that these negative outcomes reflect the lack
of selectivity in these inhibitors, resulting in interference with
other non-pathology-related physiological processes (Arlt
et al., 2002; Kruger et al., 2001).
The role of selectivity and affinity is further attested to by the
failure of the wild-type SFTI to inhibit digestion of fibrinogen by
KLK4. Hence, although the wild-type SFTI might bind with high
affinity to KLK4, it has lower selectivity than the FCQR variant
we describe. This is especially important in view of the pivotal
role that fibrinogen remodelling plays in maintenance of the
extracellular matrix and progression of cancer. Furthermore,
we propose that although wild-type SFTI might compete effi-
ciently with a short peptide for the enzyme’s active site, it is
completely ineffective when competing with a larger protein
binding with higher affinity and selectivity when compared with
the FCQR variant, with its superior selectivity as attested to by
its lack of inhibition of KLK2, 5, 12, and 14 proteolysis. The failure
of the wild-type SFTI to inhibit protein proteolysis in the context
of successful inhibition of hydrolysis of a peptide pNA also has
important implications for the way in which the inhibition of
protease activity is assessed. It is possible that this phenomenon
is restricted to certain proteases and the pNA reporter group.
However, if differential inhibition of peptide hydrolysis versus
protein hydrolysis is more general, a large number of studies
relying on inhibition of hydrolysis of model substrates might
have been erroneously extended to cover inhibition of in vivo
protein degradation.
SIGNIFICANCE
Recently PAR activity has become the focus of considerable
attention because of its demonstrated role in cellular prolif-
eration and migration in cancer cell lines, in addition to the
discovery that it is overexpressed during prostate cancer
progression. Here we have actively targeted the proteolytic
activation of PAR-2 by the serine protease KLK4 on the basis
of the temporal coexpression of these proteins (Ramsay
et al., 2008a). Our work has resulted in the first serine
protease inhibitor to selectively and potently inhibit KLK4
activation of PAR-2. One of the main challenges in protease
inhibitor design has been the ability to produce molecules
that potently inhibit target proteases but that leave other
important proteolytic processes unaffected. Although we
have not assayed all other serine proteases, we have
demonstrated the selectivity of our SFTI variant against
KLK4’s closest relatives. In contrast to conventional strate-
gies, we have used a library composed of individual peptidesr Ltd All rights reserved
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of magnitude lower than that selected from a previously
published positional scanning library. We then used the
novel strategy of substituting this sequence into the natu-
rally occurring SFTI scaffold that is already a highly potent
inhibitor of serine proteases, but lacks selectivity. Our
design strategy resulted in an inhibitor with a highly re-
stricted range of inhibitory activity but retained its potency,
achieving an IC50 value within an order of magnitude to
that of the native inhibitor for its target protease (trypsin).
Our studies have revealed that the inhibitor is extremely
robust, which, coupled to its high potency of inhibition for
KLK4 and concomitant blockade of PAR signaling, make it
an excellent candidate for further therapeutic development.
EXPERIMENTAL PROCEDURES
Sparse Matrix Peptide Library Design and Peptide Synthesis
The sparse matrix library was based on Debela and Matsumura PS-SCL
screens taking the top five scoring side chains at positions P1–P4, producing
the matrix shown in Figure 1. Analysis of the interaction of SFTI with KLK4
showed that residues beyond Arg2 (P4 position on the inhibitor, subsite S4
on the enzyme) did not contact the enzyme and hence the library was
restricted to tetrapeptides. Peptides were produced using standard solid
phase synthesis protocols with 9-fluorenylmethyl carbamate (Fmoc) as semi-
permanent protecting group. Peptide elongation was performed with 4 Eq.
Fmoc amino acids dissolved in 0.25 M each of 2-(1H-benzotriazole-1-yl)-1,
1,3,3-tetramethyluronium hexafluorophosphate, 1-hydroxybenzotriazole,
and N,N-di-isopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF).
Fmoc deprotectionwas achieved using 20%piperidine and 5%1,8-diazabicy-
clo [5.4.0]undec-7-ene DBU in DMF.
Peptide-pNAs were synthesized as previously described (Abbenante et al.,
2000), whereas peptide aldehydes were synthesized as above using H-Arg
(Boc)-H Novasyn TG resin (Novabiochem). After removal of protecting groups
with 95% trifluoroacetic acid with scavengers, cleavage was performed using
3 3 15 ml acetic acid/H2O/dichloromethane/methanol (10:5:63:21) over
45 min.
SFTI was synthesized as a linear molecule on Fmoc-Asp(ODmab)-OH
(Bachem) derivatized (0.5 mmol/g) 2-chloro trityl resin (Auspep). Using
Fmoc-Cys(STBU)-OH (Bachem) enabled selective removal of the cysteine
side chain protecting group (20 Eq dithiothreitol and 0.5 M DIPEA in DMF)
before disulfide bond formation by overnight stirring in 10 mM reduced gluta-
thione and 1mMoxidized glutathione in Tris HCl (pH 8.0). Subsequent selective
deprotection of the aspartate side chain Dmab-protecting group (five washes
of two volumes 2% hydrazine in DMF enabled on resin cyclization through
the aspartate side chain using 4 Eq each of DIPEA and 1-[Bis(dimethylamino)-
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate in
DMF. Protecting group removal and cleavage was performed using 95% tri-
fluoroacetic acid with scavengers. Lyophilized synthesis products were puri-
fied by reverse-phase HPLC from 10% isopropanol, 0.1% TFA in water with
a Spherex 5 micron C18 column (Phenomenex), eluting with a linear gradient
of 100% isopropanol and 0.1%TFAover 70min.Molecularmasseswere deter-
mined using Protein Chip Send Arrays (Bio-Rad; #C57-30081) with a Protein
Chip SELDI-TOF-MS system (Bio-Rad) in accordance with the manufacturer’s
instructions (see Supplemental Data available online).
Protein Expression and Purification
Human recombinant KLK4 was expressed in E. coli using a previously
described chimeric KLK4 plasmid construct where the native proregion was
replaced with the proregion of PSA, enabling autoactivation (Takayama
et al., 2001). Protein was expressed as inclusion bodies that were isolated
and solubilized as described previously to yield 90% pure KLK4. Protein re-
folding was performed by dilution into 100 volumes of refolding buffer I (2 M
urea, 0.1 M NaCl, 5 mM GSH, 0.5 mM GSSG, 10 mM benzamidine, 50 mM
Tris HCl [pH 8.0], 2 mM CaCl2) over 44 hr before further dilution into 3 volumesChemistry & Biology 16refolding buffer II (refolding buffer I with 0.5 M urea, 0.5 mM GSH, 0.05 mM
GSSG, 2 mM CaCl2) over another 24 hr. Dialysis was performed as previously
described (Takayama et al., 2001), with an additional 2 mM CaCl2 added to
reduce aggregation (Debela et al., 2006) before concentration using UNO
sphere Q (Bio-Rad) and eluting with Tris-buffered saline (pH 7.5)/2 mM
CaCl2. Subsequently, the material was purified to apparent homogeneity
(according to Coomassie-blue-stained SDS-PAGE) by gel filtration using
Sephacryl S-200 (GE Health Care) pre-equilibrated with 50 mM Tris-HCl
(pH 7.5), 20 mM NaCl, and 2 mM CaCl2.
Insect cell kallikrein expression constructs for KLK2, 5, and 14 were gener-
ated by ligating kallikrein open reading frames, including the pre/proregion into
the pIB/V5-His vector (Invitrogen); resulting constructs were validated by DNA
sequencing. These constructs generate the complete kallikrein amino acid
sequence followed by V5 (GKPIPNPLLGLDST) and 6x histidine tags. Insect
Sf9 cells were transfected using Cellfectin (Invitrogen) as described previously
(Ramsay et al., 2008b). Following transfection with the kallikrein-pIB/V5-His
constructs, Sf9 cells with stably integrated kallikrein-pIB constructs were
selected with 50 mg/ml Blasticidin (InvivoGen, San Diego, CA). Kallikreins
were purified from conditioned media from these cells using Ni-NTA agarose
as described by Ramsay et al. (2008a). Eluted fractions containing kallikreins,
identified by analysis of a Coomassie-stained polyacrylamide gel, were pooled
and then dialyzed against phosphate-buffered saline (PBS, pH 7.4) at 4C
overnight. Kallikreins were aliquoted and stored at 80C. Recombinant
protein was also validated by immunoblotting using anti-V5-His antibodies
to confirm the identity of purified proteins (see Supplemental Data).
Chromogenic Substrate Screen
Peptide substrates were adjusted to equimolarity according to their absor-
bance at 405nm following total hydrolysis of the pNAmoiety. Assays were per-
formed in transparent 96 microwell plates with 4.9 ng KLK4 and 12 mM
substrate in 300 ml assay buffer (0.1 M Tris HCl [pH 7.5], 0.1 M NaCl). Hydro-
lysis wasmonitored at 405 nmover 14min using aBenchmark plusmicrospec-
trophotometer (Bio-Rad).
Kinetic Studies
Active site titration was carried out according to Beynon and Bond (1989),
replacing a1-proteinase inhibitor with soybean trypsin inhibitor. Enzymatic
activity assays were performed with 4.9 nM KLK4, and substrate concentra-
tions in the range of 0–600 mM in 300 ml assay buffer with hydrolysis monitored
over 5 min as described for the substrate screen. The data were fitted to the
Michaelis-Menten equation by linear regression analysis using thePrism5 soft-
ware suite (GraphPad Software Inc.).
Inhibitor Kinetics
Recombinant kallikreins were expressed in insect cells as described above
or obtained from R&D Systems (Minneapolis, MN). All other enzymes and
substrates were obtained from Sigma Chemicals if not otherwise specified.
Insect cell KLK2 (150 ng), bacterially expressed human KLK4 (37 ng), insect
cell KLK5 (60ng), insect KLK14 (70ng), bovine b-trypsin (20 ng), bovine
thrombin (20 ng), bovine a-chymotrypsin (0.5 mg), Streptomyces griseus type
XIV protease (0.5 mg), bovine plasminogen (0.5 mg), and human matriptase
(30 ng, R&D Systems) were incubated with various concentrations of inhibitors
in 200 ml assay buffer for 10 min prior to initiation by the addition of 100 ml of
0.3 mM peptide-pNA substrates Bz-PFR-pNA: KLK2; FVQR-pNA: KLK4;
Bz-PFR-pNA: KLK5; Ac-GSLR-pNA: KLK14; BAPNA: trypsin; Bz-Phe-Val-
Arg-pNA: thrombin and matriptase; Trp-pNA: a-chymotrypsin; Leu-pNA:
Streptomyces griseus type XIV protease, and bovine plasma plasminogen.
The release of pNA moiety was monitored as described above for 7 min,
with each point being the average of three independent triplicate reactions.
IC50 was determined using the Prism 5 software suite (GraphPad Software).
Stability of SFTI-FCQR in Cell-Based Systems
Cell monolayers of LNCaP, 22Rv1 and PC3 cells were established in RPMI
1640 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin,
and 100 mg/ml streptomycin. Each cell line was treated with ± 1 mM SFTI-
FCQR contained in 4.0 ml RPMI media (as above) with a vehicle control to
account for inhibition by intrinsic media factors. Samples (250 ml) of media
were taken at 0, 24, 48, 72, 96, and 120 hr time points. Media samples were, 633–643, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 641
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move cellular debris and precipitated protein. Residual SFTI-FCQR inhibitory
activity in the medium was determined against recombinant KLK4 using
FVQR-pNA as a peptide substrate as described above using 15 ng KLK4
and 0.1 mM FVQR-pNA with 2.5 ml and 50 ml media with or without SFTI-
FCQR added from each treatment.
Protein Proteolysis
Fibrinogen was solubilized in assay buffer to a final concentration of 1 mg/ml
and digested with proteases (with or without inhibitor) over varying periods
at 37C. Typically assays consisted of 5 mM protein substrate and 1–125 nM
protease made up to a final volume of 8 ml with assay buffer. Proteolysis
was initiated by addition of protease and terminated by addition of SDS-
PAGE sample buffer and heat denaturation at 100C for 5 min. Hydrolysis
products were resolved on 12% SDS-PAGE gels and compared with incuba-
tions terminated immediately after initiation (time 0). The following incubation
times and protease concentrations were used in this study: KLK2, 252 nM
over 90 min; KLK4, 2.5 nM over 90 min, KLK5, 75 nM over 3 hr; KLK12
1.15 mM over 3 hr; KLK14, 125nM over 90 min; trypsin, 1 nM over 16 min.
Measurement of Changes in Intracellular Ca2+
Lungmurine fibroblasts from PAR-1-null mice stably expressing human PAR-2
were grown to 80% confluence as previously described (Ramsay et al.,
2008b), washed with PBS, detached nonenzymatically, resuspended (43 106
cells/ml) in extracellular medium (121 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2,
1.8 mM CaCl2, 5.5 mM glucose, 25 mM HEPES [pH 7.4]) containing 0.2%
(w/v) bovine serum albumin (Sigma), and then loaded with the fluorescence
indicator Fura-2 acetoxymethyl ester (1.0 mM; Invitrogen) at room temperature
for 60 min. Cells were then pelleted followed by resuspension in extracellular
medium (without bovine serum albumin) at a concentration of 23 106 cells/ml
for fluorescence measurements. The ratio of fluorescence at 510 nm after
excitation at 340 and 380 nm was monitored (Polarstar Optima fluorescent
plate reader) during treatment with bovine b trypsin (Sigma Chemicals),
PAR-2-activating peptide SLIGKV (AusPep), and iKLK4 with or without 1 mM
SFTI-FCQR.
Molecular Modeling
All modeling and superpositions were performed using COOT (Emsley and
Cowtan, 2004). Residue packing and interatomic clashes were visualized
and monitored in COOT using the programs REDUCE and PROBE (Davis
et al., 2004). First, a KLK4-SFTI complex was modeled by superimposing
KLK4 (Protein Data Bank [PDB] ID code 2BDG, chain A) with the trypsin chain
of a trypsin-SFTI complex (PDB ID 1SFI) and removing any unfavorable inter-
actions by conjugate gradient energy minimization with the program CNS
(Brunger et al., 1998). Backbone atoms of both the protease and SFTI-
FCQR molecule were fixed, in light of the rigidity of the inhibitor and structural
conservation of KLK4 with trypsin, whereas side chains were subject to
harmonic restraints. Molecular surfaces were created using CCP4MG (Potter-
ton et al., 2004) and color coded according to electrostatic potential (calcu-
lated by the Poisson-Boltzmann solver within CCP4MG). The probe radius
used was 1.4 A˚. The resulting molecular surfaces were rendered using
POVRAY (www.povray.org) (Figures 5 D and 5E). PyMol (http://pymol.
sourceforge.net/newman/user/toc.html) was used to produce Figures 5A–5C.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and three
figures and can be found with this article online at http://www.cell.com/
chemistry-biology/supplemental/S1074-5521(09)00175-6.
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